设为首页 加入收藏

TOP

Brinavess 20mg/ml solution infusion(维那卡兰冻干粉注射剂)
药店国别  
产地国家 法国 
处 方 药: 是 
所属类别 20mg/ml 500mg 
包装规格 20mg/ml 500mg 
计价单位: 瓶 
生产厂家中文参考译名:
Correvio UK Ltd
生产厂家英文名:
Correvio UK Ltd
该药品相关信息网址1:
http://www.oneyao.net/article/2012/0118/28337.html
该药品相关信息网址2:
http://www.ncpe.ie/drugs/vernakalant-brinavess/
该药品相关信息网址3:
http://www.drugs.com/international/brinavess.html
原产地英文商品名:
Brinavess 20 mg/ml Solution Concentrated for Infusion
原产地英文药品名:
500 mg Vernakalant HCL, equivalent to 452.5mg Vernakalant-Free Base
中文参考商品译名:
BRINAVESS 静脉注射剂 20毫克/毫升 500毫克
中文参考药品译名:
vernakalant hydrochloride
曾用名:
简介:

 

部份中文维那卡兰处方资料(仅供参考)
英文名:vernakalant HCl, IV
商品名:Brinavess
中文名:维那卡兰冻干粉注射剂
生产商:Correvio UK Ltd
药品简介
Brinavess 20mg/ml浓缩液用于输液
定性和定量
组成BRINAVESS每毫升浓缩液中含有20mg盐酸维那卡兰,相当于18.1mg vernakalant。每个10毫升小瓶含有200毫克盐酸维那卡兰,相当于181毫克维那卡兰。每个25毫升小瓶含有500毫克盐酸维那卡兰,相当于452.5毫克维那卡兰。稀释后,溶液的浓度为4mg/ml盐酸维那卡兰。
具有已知作用的赋形剂:每200mg小瓶含有约1.4mmol(32mg)的钠。每个500mg小瓶含有约3.5mmol(80mg)的钠。每ml稀释溶液含有约3.5mg钠(注射用氯化钠溶液9mg / ml(0.9%)),0.64mg钠(注射用5%葡萄糖溶液)或3.2mg钠(乳酸林格氏液)注射)。有关辅料的完整列表,请参阅第6.1节。
适应症
最近发生的心房颤动迅速转变为成人窦性心律。
- 对于非手术患者:心房颤动持续时间≤7天; -对于心脏手术后的患者:心房颤动的持续时间≤3天。
剂量和给药方法
最近发生的心房颤动迅速转变为成人窦性心律。
-对于非手术患者:心房颤动持续时间≤7天; - 对于心脏手术后的患者:心房颤动的持续时间≤3天。
术语和给药方法BRINAVESS必须通过静脉输注在适合心脏复律的受控临床环境中给药。只有合格的医疗保健专业人员才能使用BRINAVESS,并应在输液后至少15分钟内经常监测患者,以了解血压或心率突然降低的迹象和症状。该药物包含预先输注检查表。在给药之前,要求开处方者使用提供的检查表确定患者是否有资格接受给药。必须在输液容器上确认该检查表,并由管理BRINAVESS的医疗保健提供者阅读。剂量BRINAVESS的剂量取决于患者的体重,最大计算剂量基于113 kg。推荐的第一次输注是3mg/kg输注。
https://www.medicines.org.uk/emc/product/7249/smpc 
Brinavess 20 mg/ml concentrate for solution for infusion
MSD (known in the US and Canada as Merck) (NYSE:MRK) and Cardiome Pharma Corp. (NASDAQ: CRME/ TSX: COM) announced that the intravenous (IV) formulation of BRINAVESS™ (vernakalant) has been granted marketing approval in the European Union (EU), Iceland and Norway for the conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults.
The full indication is for the rapid conversion of recent onset AF to sinus rhythm in adults: for non-surgery patients with AF of seven days or less and for post-cardiac surgery patients with AF of three days or less.
The new treatment has a unique mechanism of action from other AF medicines and is the first product in a new class of pharmacologic agents for cardioversion of AF to launch in the EU.
"BRINAVESS is the first and only agent that acts preferentially in the atria. This medicine offers physicians, patients and hospitals an important new therapy option to use for the rapid treatment of recent-onset AF, and we are pleased to add this to our strong portfolio of medicines for cardiovascular disease," said Patrick Magri, senior vice president, general manager, Cardiovascular Franchise, Merck. "We welcome this important milestone in our collaboration with Cardiome and we are planning to make the product available in the EU by the end of the year."
"BRINAVESS is the first pharmacologic innovation for recent onset of AF in over ten years, and European approval is an exciting juncture for Cardiome." said Doug Janzen, president and chief executive officer of Cardiome. This success was made possible through the commitment and hard work of our employees and our partner Merck, the support of our shareholders, and the efforts of many dedicated medical professionals and patients who have taken part in the clinical program."
Information on the clinical program for vernakalant
The approval of vernakalant is based on the results of three randomized, double-blind, placebo-controlled studies (ACT I, ACT II, and ACT III) and an active comparator trial (AVRO).
In ACT I and III, the efficacy of vernakalant at converting patients from AF to sinus rhythm for a minimum duration of one minute within 90 minutes of initiating therapy was eva luated in 390 haemodynamically stable adult patients with short duration AF (3 hours to 7 days) versus placebo. In ACT I, vernakalant cardioverted 51.0 percent of patients versus 4.0 percent of patients taking placebo (n=74 and 3, respectively; p<0.0001). In ACT III, vernakalant cardioverted 51.2 percent of patients versus 3.6 percent of patients taking placebo (n=44 and 3, respectively; p <0.0001). Conversion of AF to sinus rhythm occurred rapidly; in responders, the median time to conversion was 10 minutes from start of first infusion based on pooled results from the ACT I and ACT III studies.
The efficacy of vernakalant also was studied in ACT II in 150 patients with sustained AF (3 hours to 72 hours duration) that occurred between 24 hours and 7 days post coronary artery bypass graft and/or valvular surgery. Treatment with vernakalant effectively converted 47.0 percent of patients from AF to sinus rhythm versus 14.0 percent with placebo (p=0.0001).
Ads by Google
Mission3 GlobalTrack GxPD - A complete solution for xEVMPD - available immediately - www.mission3.com
Dental Occlusion Analysis - Easily eva luate Dental Occlusion with T-Scan® Occlusal Analysis - www.Tekscan.com/Occlusal-Analysis
Book Flights with Ctrip - China's Leading Booking Engine. Your global home for China travel. - flights.english.ctrip.com
In the AVRO study, vernakalant was significantly more effective than amiodarone IV in providing rapid conversion to sinus rhythm within 90 minutes of initiating therapy
In the AVRO (Active-Controlled, Multi-Center Study of Vernakalant Injection versus Amiodarone in Subjects with Recent Onset Atrial Fibrillation) study, vernakalant was demonstrated to be significantly faster than amiodarone IV in restoring AF patients to sinus rhythm. In the trial, vernakalant was studied in 116 patients with AF (3 hours to 48 hours) versus 116 patients on amiodarone. The amiodarone infusion was given over two hours (i.e., one hour loading dose of 5 mg/kg, followed by one hour maintenance infusion of 50 mg) with the objective to compare rapid conversion to sinus rhythm. The primary endpoint was the proportion of patients that achieved sinus rhythm for a minimum duration of one minute within 90 minutes of first exposure of the study drug. In this study, treatment with vernakalant converted 51.7 percent of patients to sinus rhythm at 90 minutes versus 5.2 percent with amiodarone.
Important Safety Information
Vernkalant is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients. Vernakalant also is contraindicated in patients with severe aortic stenosis, systolic blood pressure <100 mm Hg, and heart failure class NYHA III and NYHA IV. Furthermore, vernakalant is contraindicated in patients with prolonged QT at baseline (uncorrected >440 msec), severe bradycardia, sinus node dysfunction, or second-degree or third-degree heart block in the absence of a pacemaker. Vernakalant is also contraindictated in patients who use intravenous rhythm control antiarrhythmics (class I and class III) within four hours prior to administration of vernakalant and patients with acute coronary syndrome (including myocardial infarction) within the last 30 days.
Vernakalant is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients; patients with severe aortic stenosis, patients with systolic blood pressure <100 mm Hg, and patients with heart failure class NYHA III and NYHA IV and patients with prolonged QT at baseline (uncorrected >440 msec), severe bradycardia, sinus node dysfunction, or second-degree or third-degree heart block in the absence of a pacemaker. Vernakalant is also contraindicated in patients who use intravenous rhythm control antiarrhythmics (class I and class III) within four hours prior to administration of BRINAVESS and patients with acute coronary syndrome (including myocardial infarction) within the last 30 days.
Patients should be observed with assessment of vital signs and continuous cardiac rhythm monitoring during and after administration of vernakalant, until clinical and ECG parameters have stabilised.
Hypotension can occur in a small number of patients (vernakalant 7.6%, compared to placebo 5.1%). Hypotension typically occurs early, either during the infusion or early after the end of the infusion, and can usually be corrected by standard supportive measures. Patients with congestive heart failure (CHF) have been identified as a population at higher risk for hypotension.
Patients with a history of CHF showed a higher incidence of ventricular arrhythmia in the first 2 hours post dose (7.3% for vernakalant compared to 1.6% for placebo). These arrhythmias typically presented as asymptomatic, monomorphic, non-sustained (average 3 to 4 beats) ventricular tachycardias. By contrast, ventricular arrhythmias were reported with similar frequencies in patients without a history of CHF who were treated with either vernakalant or placebo (3.2% for vernakalant versus 3.6% for placebo).
In patients with valvular heart disease, there was a higher incidence of ventricular arrhythmia events in patients on BRINAVESS. These patients should be monitored closely.
As a precautionary measure, it is preferable to avoid the use of BRINAVESS during pregnancy. It is unknown whether vernakalant/metabolites are excreted in human milk. Caution should be exercised when used in breast-feeding women.
In clinical studies, the most commonly reported adverse reactions (greater than 5%) seen in the first 24 hours after receiving BRINAVESS were dysgeusia (taste disturbance 20.1%), sneezing (14.6 percent), and paraesthesia (9.7%).
Clinically significant adverse reactions observed in clinical trials included hypotension and ventricular arrhythmia.
Before initiating therapy, the full prescribing information should be consulted.
Merck-Cardiome Agreement
In April 2009, Cardiome and Merck announced a collaboration and license agreement for the development and commercialization of vernakalant. The agreement provides Merck, Sharp and Dohme Corp. (formerly known as Merck & Co., Inc.) with exclusive global rights to vernakalant oral formulation for the maintenance of normal heart rhythm in patients with AF, and provides another Merck affiliate, Merck Sharp & Dohme (Switzerland) GmbH, with exclusive rights outside of the United States, Canada and Mexico to vernakalant IV formulation for rapid conversion of recent onset AF to sinus rhythm in adults.
Source:
Cardiome Pharma Corp.
Merck
https://www.medicines.org.uk/emc/product/7249/smpc
-------------------------------------------------
附件:
20136222060113.pdf 

】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
分享到QQ空间
分享到: 
上一篇Brinavess 20mg/ml Infusionsl(盐.. 下一篇没有了

相关栏目

最新文章

图片主题

热门文章

推荐文章